Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual CD38 and BCMA CAR-T in R/R Multiple Myeloma
NCT03767751Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2018
- Primary completion
- Dec 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of dual specificity CD38 and BCMA CAR-T cells in multiple myeloma (MM), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
dual specificity CD38 and BCMA CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03767751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03767751.